Clinical Trials

NCT Number: NCT04656678 Phase: Not Applicable Trial Summary: The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Northwell Health Acronym:

NCT Number: NCT05219500 Phase: Phase 2 Trial Summary: The treatment regimen will consist of 4 doses of 225Ac-PSMA- – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Fusion Pharmaceuticals Inc. Acronym: TATCIST

NCT Number: NCT05348577 Phase: Phase 3 Trial Summary: This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mC – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): AstraZeneca Acronym: CAPItello280

NCT Number: NCT05081193 Phase: Phase 2 Trial Summary: Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone ma – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Acronym:

NCT Number: NCT05245006 Phase: Phase 1 Trial Summary: CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Robert Flavell, MD, PhD Acronym:

NCT Number: NCT05283330 Phase: Phase 1 Trial Summary: A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of 212Pb-DOTAM-GRPR1 in subjects with various GRPR-exp – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Orano Med LLC Acronym:

NCT Number: NCT05413850 Phase: Phase 1|Phase 2 Trial Summary: To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Blue Earth Therapeutics Ltd Acronym:

NCT Number: NCT05479578 Phase: Phase 1 Trial Summary: This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rashmi Verma, MD Acronym:

NCT Number: NCT03972657 Phase: Phase 1|Phase 2 Trial Summary: The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in D – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Regeneron Pharmaceuticals Acronym:

NCT Number: NCT04363164 Phase: Phase 2 Trial Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Acronym: